Y Intercept (Hong Kong) LTD Acadia Pharmaceuticals Inc Transaction History

Y Intercept (Hong Kong) LTD

$1.58 Billion
Q3 2024

A detailed history of Y Intercept (Hong Kong) LTD transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Y Intercept (Hong Kong) LTD holds 50,544 shares of ACAD stock, worth $872,389. This represents 0.05% of its overall portfolio holdings.

Number of Shares

50,544

Previous 89,789 43.71%

Holding current value

$872,389

Previous $1.46 Million 46.74%

% of portfolio

0.05%

Previous 0.08%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$15.14 - $19.14 $594,169 - $751,149	-39,245 Reduced 43.71%	50,544 $777,000
Q2 2024 Aug 14, 2024	SELL	$14.62 - $18.42 $755,079 - $951,337	-51,647 Reduced 36.52%	89,789 $1.46 Million
Q1 2024 May 10, 2024	BUY	$17.79 - $30.86 $2.52 Million - $4.36 Million	141,436 New	141,436 $2.62 Million
Q3 2023 Nov 14, 2023	BUY	$20.84 - $33.47 $1.02 Million - $1.64 Million	48,928 Added 245.14%	68,887 $1.44 Million
Q2 2023 Aug 14, 2023	SELL	$17.8 - $25.65 $145,782 - $210,073	-8,190 Reduced 29.1%	19,959 $478,000
Q1 2023 May 09, 2023	BUY	$16.32 - $20.92 $69,947 - $89,663	4,286 Added 17.96%	28,149 $529,000
Q4 2022 Feb 14, 2023	SELL	$14.2 - $18.63 $74,947 - $98,329	-5,278 Reduced 18.11%	23,863 $379,000
Q3 2022 Feb 14, 2023	BUY	$14.11 - $18.27 $212,651 - $275,347	15,071 Added 107.11%	29,141 $476,000
Q2 2022 Aug 08, 2022	BUY	$13.01 - $27.22 $54,238 - $113,480	4,169 Added 42.11%	14,070 $198,000
Q1 2022 May 16, 2022	SELL	$20.94 - $27.5 $2,052 - $2,695	-98 Reduced 0.98%	9,901 $240,000
Q4 2021 Feb 14, 2022	BUY	$16.79 - $27.09 $167,883 - $270,872	9,999 New	9,999 $233,000

Others Institutions Holding ACAD

# of Institutions

281

Shares Held

156M

Call Options Held

901K

Put Options Held

314K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.79B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.

Account

Y Intercept (Hong Kong) LTD Acadia Pharmaceuticals Inc Transaction History